TG Therapeutics Inc
General ticker "TGTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.8B
TG Therapeutics Inc follows the US Stock Market performance with the rate: 58.8%.
Estimated limits based on current volatility of 4.5%: low 30.47$, high 33.34$
Factors to consider:
- Current price 101.0% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [6.81$, 16.02$]
- 2024-12-30 to 2025-12-30 estimated range: [4.68$, 11.66$]
Financial Metrics affecting the TGTX estimates:
- Negative: Non-GAAP EPS, $ of 0.02 <= 0.10
- Negative: Operating cash flow per share per price, % of -1.39 <= 2.35
- Positive: 1.03 < Operating profit margin, % of 8.83
- Positive: 2.86 < Return on assets ratio (scaled to [-100,100]) of 3.70
- Negative: Industry operating profit margin (median), % of -98.30 <= 2.14
- Positive: Interest expense per share, $ of 0.09 <= 0.14
Short-term TGTX quotes
Long-term TGTX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $6.69MM | $2.79MM | $233.66MM |
| Operating Expenses | $351.46MM | $195.62MM | $213.03MM |
| Operating Income | $-344.77MM | $-192.84MM | $20.63MM |
| Non-Operating Income | $-3.33MM | $-5.50MM | $-7.57MM |
| Interest Expense | $5.64MM | $10.19MM | $12.62MM |
| R&D Expense | $198.53MM | $112.13MM | $76.19MM |
| Income(Loss) | $-348.10MM | $-198.34MM | $13.06MM |
| Taxes | $7.45MM | $5.50MM | $0.39MM |
| Profit(Loss) | $-355.55MM | $-203.83MM | $12.67MM |
| Stockholders Equity | $237.15MM | $58.59MM | $160.50MM |
| Inventory | $23.60MM | $0.00MM | $39.82MM |
| Assets | $379.63MM | $193.57MM | $329.59MM |
| Operating Cash Flow | $-295.63MM | $-176.17MM | $-31.41MM |
| Capital expenditure | $0.40MM | $0.01MM | $0.00MM |
| Investing Cash Flow | $-0.33MM | $-20.01MM | $-50.65MM |
| Financing Cash Flow | $41.42MM | $-0.39MM | $72.70MM |
| Earnings Per Share* | $-2.69 | $-1.51 | $0.09 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.